Purdue Pharma and the Sacklers: The Opioid Settlement and Harrington v. Purdue Pharma

Case at a Glance

Purdue Pharma Settlement Case Brief: The Sacklers, the Bankruptcy, and the Opioid Payout Explained

Purdue Pharma, the maker of OxyContin, and its owners, the Sackler family, reached a $7.4 billion opioid settlement in 2025 after years of bankruptcy litigation that included a landmark U.S. Supreme Court ruling. The case, sometimes searched as perdue pharma or the sacklers, is one of the largest and most closely watched corporate accountability settlements connected to the American opioid crisis.

This case brief covers the purdue pharma lawsuit, the sackler family lawsuit, the Supreme Court's 2024 decision in Harrington v. Purdue Pharma, and the latest opioid settlement news, including how much individuals may receive and when payments are expected to begin.

What Is the Purdue Pharma Settlement?

The Purdue Pharma settlement is a $7.4 billion bankruptcy agreement between Purdue Pharma, the Sackler family, and 55 state and territorial attorneys general to resolve thousands of lawsuits over the company's role in the opioid crisis. The purdue pharma settlement, confirmed by a federal bankruptcy judge on November 18, 2025, followed years of litigation, including a 2024 U.S. Supreme Court ruling that struck down an earlier version of the deal.

Who Are the Sacklers?

The Sacklers are the family that owned and controlled Purdue Pharma for decades, including Richard Sackler, Mortimer Sackler, and Raymond Sackler, who led the company during its aggressive marketing of OxyContin. The broader sackler lawsuit history and the related sackler family lawsuit trace back to Purdue's 1995 approval and release of OxyContin, a powerful prescription opioid painkiller that the family and company are widely accused of marketing in ways that minimized its addiction risks. Approximately 247,000 people in the United States died from prescription-opioid overdoses between 1999 and 2019, and Purdue and the Sacklers have faced sustained legal pressure over their alleged role in that public health crisis.

What Happened to Purdue Pharma?

Purdue Pharma filed for Chapter 11 bankruptcy in September 2019 after being sued by numerous state, tribal, and local governments over its role in the opioid crisis. Filing for bankruptcy automatically paused all pending litigation against Purdue and, through a bankruptcy court order, also paused lawsuits filed directly against members of the Sackler family. Between 2019 and 2021, Purdue, the Sacklers, and major creditor groups negotiated a restructuring plan.

The bankruptcy court approved an initial version of this plan in September 2021. However, a group of states and the U.S. Trustee, an official within the Department of Justice, objected and appealed, arguing the bankruptcy court lacked authority to release the Sacklers from personal civil liability without the consent of the people who might otherwise sue them. A federal district court agreed with the objectors in December 2021 and vacated the plan, sending the case back into years of further appeals.

Harrington v. Purdue Pharma: The Supreme Court Ruling

In Harrington v. Purdue Pharma L.P., decided June 27, 2024, the U.S. Supreme Court ruled 5-4 that the Bankruptcy Code does not allow a bankruptcy court to release non-bankrupt third parties, like the Sackler family, from civil lawsuits without the consent of the people bringing those claims. The case, formally titled William K. Harrington, United States Trustee, Region 2 v. Purdue Pharma L.P., addressed whether Chapter 11 permitted this kind of nonconsensual third-party release as part of a reorganization plan.

Justice Neil Gorsuch wrote the majority opinion, holding that this practice broke a basic tenet of bankruptcy law because the Sacklers themselves had never personally filed for bankruptcy, yet the original plan would have given them sweeping legal protection anyway. The ruling effectively struck down the prior settlement structure that would have shielded the Sacklers from all future opioid-related lawsuits in exchange for a $6 billion contribution.

The New Purdue Pharma Settlement: $7.4 Billion

Following the Supreme Court's 2024 ruling, Purdue Pharma and the Sackler family returned to negotiations and filed a new bankruptcy plan in 2025 that raised the total settlement value to at least $7.4 billion. All 50 states, the District of Columbia, and U.S. territories eventually agreed to the revised terms, along with roughly 9,300 participating local governments.

U.S. Bankruptcy Judge Sean Lane formally confirmed the new Purdue Pharma bankruptcy plan on November 18, 2025, finalizing the $7.4 billion settlement between the company, the Sackler family, and the coalition of state attorneys general. New York Attorney General Letitia James led negotiations on behalf of the states. Under the confirmed plan, the Sackler family will pay up to $7 billion over 15 years, while Purdue itself will contribute the remaining amount from its own assets.

What Happens to Purdue Pharma Now?

As part of the settlement, the Sackler family will give up all ownership and involvement in Purdue Pharma, and the company will be restructured into a new, independent public benefit entity called Knoa Pharma. The reorganized company remains barred from marketing opioid products, from lobbying government officials, and from using opioid sales figures to calculate employee bonuses. A court-appointed monitor will oversee its operations to ensure ongoing compliance with these restrictions.

When Will Individuals Receive Settlement Money From Purdue Pharma?

The first settlement payments were expected to begin in early 2026, pending final approval steps, with the Sacklers paying $1.5 billion and Purdue paying roughly $900 million in that initial round. Subsequent payments are structured at $500 million after one year, another $500 million after two years, and $400 million after three years, continuing across the full 15-year payment schedule. A dedicated pool of about $850 million has been set aside specifically for individual victims and family members, separate from the much larger amounts directed to state and local governments for opioid abatement programs.

Opioid Settlement for Individuals: How Much Will I Get?

Individual payouts from opioid settlements, including the Purdue Pharma settlement, vary significantly and tend to be far smaller than the multibillion-dollar headline settlement figures suggest, since the bulk of the money is directed to state and local governments rather than to individual claimants. Reporting on similar bankruptcy settlements, including Mallinckrodt's, shows that after administrative fees charged by the settlement trust and attorney's fees are deducted, many individual claimants have received amounts in the range of several hundred to a few thousand dollars, rather than large personal payouts. There is no fixed purdue pharma claims payout per person calculator that guarantees a specific amount, since individual payments depend on the number of approved claims, the documentation provided, and the trust's distribution formula.

Mallinckrodt Opioid Settlement: A Separate Case

Mallinckrodt is a separate generic opioid manufacturer with its own distinct bankruptcy settlement and opioid personal injury trust, unrelated to Purdue Pharma's ownership or the Sackler family. Mallinckrodt filed for Chapter 11 bankruptcy in 2020, and its reorganization plan, which created the Mallinckrodt Opioid Personal Injury Trust, took effect on June 16, 2022. As of the most recent public reporting, Mallinckrodt was the first major opioid manufacturer to actually begin paying individual victims, though most approved claims were not expected to be fully paid out until the end of 2026. Because search interest often groups Mallinckrodt and Purdue together, it is worth being clear that a mallinckrodt opioid settlement update today reflects Mallinckrodt's own separate trust and timeline, not Purdue's.

Who Makes Oxycodone?

Oxycodone is manufactured by multiple pharmaceutical companies, not just Purdue Pharma, since it is a generic opioid compound available from several manufacturers in addition to Purdue's branded OxyContin formulation. Purdue Pharma developed and marketed OxyContin, its extended-release oxycodone product, starting in 1995, but other companies, including Mallinckrodt, have also manufactured oxycodone-based products sold under different brand names and as generics.

Purdue Pharma Bankruptcy: Where Is Purdue Pharma Located?

Purdue Pharma is headquartered in Stamford, Connecticut, and its bankruptcy case has been handled in the U.S. Bankruptcy Court for the Southern District of New York. The company's restructuring proceedings, including the confirmation hearings for both the original and revised settlement plans, took place primarily in the White Plains, New York, federal courthouse.

Legal Significance of the Purdue Pharma Case

The Purdue Pharma case, and specifically the Supreme Court's ruling in Harrington v. Purdue Pharma, reshaped how bankruptcy courts across the country can structure mass-tort settlements involving corporate owners who have not personally filed for bankruptcy. Several legal principles stand out.

Nonconsensual Third-Party Releases

The Supreme Court's ruling limits the ability of bankruptcy courts to grant sweeping legal immunity to non-bankrupt individuals, like the Sacklers, without the consent of the people who hold claims against them, a decision with implications far beyond the opioid crisis for any mass-tort bankruptcy settlement that relies on similar third-party liability shields.

Bankruptcy as a Mass-Tort Resolution Tool

The case highlights the tension between using Chapter 11 bankruptcy to efficiently resolve thousands of individual lawsuits at once and ensuring that individual claimants retain their constitutional right to pursue their own claims against parties who never filed for bankruptcy themselves.

State Attorneys General Coordination

The eventual agreement among all 50 states, the District of Columbia, and U.S. territories illustrates how coordinated multistate litigation can produce a unified settlement even after years of legal setbacks and a major Supreme Court reversal.

Individual Victim Compensation in Mass Settlements

The relatively modest payouts expected for individual claimants, compared to the much larger amounts directed to government abatement programs, reflects a recurring structural challenge in mass-tort bankruptcy settlements, where the sheer number of claimants dilutes the dollar amount each person ultimately receives.

Common Search Terms for the Purdue Pharma Case

People search for this case using many different phrasings. Settlement-focused variations include purdue settlement, purdue opioid settlement, purdue pharma opioid settlement, purdue pharma settlements, purdue pharma settles, sackler settlement, sacklers settlement, sackler family settlement, sackler settlement 2025, purdue settlement update, purdue pharma settlement update, purdue sackler, purdue pharma sackler, purdue pharma sackler opioid settlement, purdue pharma sackler family settlement, sackler family purdue pharma, and perdue pharma settlement, a common misspelling of Purdue. Lawsuit and litigation variations include purdue lawsuit, purdue lawsuits, lawsuit purdue pharma, purdue oxycontin lawsuit, purdue pharma oxycontin lawsuit, purdue opioid lawsuit, purdue oxy lawsuit, purdue pharma litigation, purdue lawsuit update, purdue pharma lawsuit updates, purdue pharma lawsuit update today, opiate lawsuit, lawsuit oxycontin, oxy lawsuit settlement, oxycontin litigation, oxycontin settlement, oxy settlement, purdue oxycontin settlement, purdue oxy settlement, and andrews and thornton purdue lawsuit, a reference to one of several law firms representing individual claimants in the litigation. News and status-update variations include purdue pharma news, purdue pharma update today, opioid settlement news, opioid settlement news october 2025, what happen to purdue pharma, purdue bankruptcy, purdue pharmaceutical, harrington v purdue pharma, and purdue pharma settlement payout date. Individual payout variations include opioid settlement for individuals how much will i get, opioid settlement family, opioid family lawsuit, when will individuals receive settlement from purdue pharma, when will individuals receive settlement from purdue pharma 2024, purdue pharma settlement payout per person, and purdue pharma individual claims payout.

Frequently Asked Questions

What is the Purdue Pharma settlement?

The Purdue Pharma settlement is a $7.4 billion bankruptcy agreement between Purdue Pharma, the Sackler family, and state governments to resolve opioid-related lawsuits, confirmed by a bankruptcy judge in November 2025.

Who are the Sacklers?

The Sacklers are the family that owned and controlled Purdue Pharma, the maker of OxyContin, for decades before the company's bankruptcy.

What was Harrington v. Purdue Pharma about?

Harrington v. Purdue Pharma was a 2024 Supreme Court case that ruled bankruptcy courts cannot release non-bankrupt parties, like the Sacklers, from civil lawsuits without the consent of claimants.

Did the Sacklers have to pay?

Yes, the Sacklers agreed to pay up to $7 billion over 15 years as part of the final settlement, in addition to giving up all ownership of Purdue Pharma.

How much did the Sackler family make off OxyContin?

Reporting has estimated the Sackler family withdrew billions of dollars in profits from Purdue Pharma over the years OxyContin was aggressively marketed, though the exact total figure has been disputed in litigation.

What happened to Purdue Pharma?

Purdue Pharma filed for bankruptcy in 2019 and, under its confirmed settlement plan, will be restructured into a new public benefit company called Knoa Pharma, with the Sackler family no longer involved.

When will individuals receive a settlement from Purdue Pharma?

Individual payments were expected to begin in 2026, drawn from an approximately $850 million pool set aside specifically for victims and their families.

How much will I get from the opioid settlement as an individual?

Individual opioid settlement payouts vary and tend to be modest compared to headline settlement totals, often in the range of a few hundred to a few thousand dollars after fees, based on patterns seen in similar bankruptcy trusts.

What is the Purdue Pharma claims payout per person?

There is no fixed payout per person; individual amounts depend on the number of approved claims, supporting documentation, and the settlement trust's distribution formula.

Is Mallinckrodt the same as Purdue Pharma?

No, Mallinckrodt is a separate opioid manufacturer with its own bankruptcy settlement and personal injury trust, unrelated to Purdue Pharma or the Sackler family.

What is the Mallinckrodt opioid settlement payout amount for individuals?

Mallinckrodt individual payouts have varied, with some claimants receiving between roughly $400 and $700 after administrative and attorney fees were deducted, according to lawyers representing claimants.

Who makes oxycodone?

Oxycodone is made by multiple pharmaceutical manufacturers, including Purdue Pharma, which sells the branded extended-release version called OxyContin, and other companies that produce generic versions.

Where is Purdue Pharma located?

Purdue Pharma is headquartered in Stamford, Connecticut, and its bankruptcy case has been handled in federal bankruptcy court in the Southern District of New York.

What is the current status of the Purdue Pharma lawsuit?

The Purdue Pharma lawsuit was resolved through a confirmed $7.4 billion bankruptcy settlement in November 2025, following the Supreme Court's 2024 rejection of an earlier settlement structure.

Did Purdue Pharma admit wrongdoing in its settlement?

Purdue Pharma previously pleaded guilty to federal criminal charges tied to its opioid marketing in 2020, separate from the civil bankruptcy settlement, which primarily resolves financial liability rather than serving as a new admission of guilt.

What is the Purdue PI Trust?

The Purdue PI Trust refers to the personal injury trust structure established under the settlement to process and pay individual victim claims connected to Purdue Pharma's opioid products.

Final Takeaway

The Purdue Pharma settlement traces a long legal path from the company's September 2019 bankruptcy filing through a landmark 2024 Supreme Court ruling in Harrington v. Purdue Pharma that struck down the Sackler family's original liability shield. A revised $7.4 billion settlement, confirmed by the bankruptcy court on November 18, 2025, will see the Sacklers pay up to $7 billion over 15 years while giving up all ownership of the company, which will be restructured into a new nonprofit-style entity. Individual victims are expected to begin receiving a share of a roughly $850 million pool starting in 2026, though individual payouts are likely to be far smaller than the massive headline settlement figure suggests.